Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $1.29, with 4.92 million shares of worth about $6.35 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 82.77% during that period and on July 16, 2025 the price saw a gain of about 12.17%. Currently the company’s common shares owned by public are about 363.18M shares, out of which, 177.00M shares are available for trading.
Stock saw a price change of 20.56% in past 5 days and over the past one month there was a price change of 92.11%. Year-to-date (YTD), LXRX shares are showing a performance of -30.65% which increased to 74.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $2.45 during that period. The average intraday trading volume for Lexicon Pharmaceuticals Inc shares is 4.87 million. The stock is currently trading 37.93% above its 20-day simple moving average (SMA20), while that difference is up 68.07% for SMA50 and it goes to 50.37% higher than SMA200.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) currently have 363.18M outstanding shares and institutions hold larger chunk of about 26.55% of that.
The stock has a current market capitalization of $468.50M and its 3Y-monthly beta is at 1.16. It has posted earnings per share of -$0.51 in the same period. It has Quick Ratio of 2.22 while making debt-to-equity ratio of 0.86. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXRX, volatility over the week remained 11.17% while standing at 10.83% over the month.
Analysts are in expectations that Lexicon Pharmaceuticals Inc (LXRX) stock would likely to be making an EPS of -0.08 in the current quarter, while forecast for next quarter EPS is -0.08 and it is -0.36 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.1 which is -0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.17 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 49.60% while it is estimated to increase by 2.36% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on March 05, 2025 offering a Market perform rating for the stock and assigned a target price range of between $2 and $1 to it. Coverage by H.C. Wainwright stated Lexicon Pharmaceuticals Inc (LXRX) stock as a Buy in their note to investors on June 17, 2024, suggesting a price target of $10 for the stock. On April 30, 2024, Leerink Partners Initiated their recommendations, while on March 07, 2023, Jefferies Initiated their ratings for the stock with a price target of $3. Stock get an Overweight rating from Piper Sandler on August 12, 2022.
